Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study

BACKGROUND: Relugolix, an oral gonadotrophin-releasing hormone receptor antagonist, was launched in Japan in 2019. Although there have been several studies on relugolix for leiomyomas, few have focused on submucosal leiomyomas. Submucosal leiomyomas cause bleeding more frequently than leiomyomas in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Yoshimitsu, Takei, Yuji, Minezumi, Takumi, Hirashima, Hiroto, Fujiwara, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015954/
https://www.ncbi.nlm.nih.gov/pubmed/36922784
http://dx.doi.org/10.1186/s12905-023-02241-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015954/
https://www.ncbi.nlm.nih.gov/pubmed/36922784
http://dx.doi.org/10.1186/s12905-023-02241-2

Ejemplares similares